Sales & Marketing News | pharmaphorum

News

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.

News

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits.

News

Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.

News

Novartis CEO Vas Narasimhan says the company is equipped to ride out "the largest patent expiry" in its history," but 2026 will still be tricky.

News

The UK confirms that the cost of the drug pricing deal with the US, initially around £1bn over three years, will be borne by the health department.

News

FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.